Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Determine If a New Shigella Vaccine is Safe, Induces Immunity and The Best Dose Among Kenyan Infants

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04056117
Recruitment Status : Recruiting
First Posted : August 14, 2019
Last Update Posted : September 9, 2019
Sponsor:
Collaborators:
Kenya Medical Research Institute
KEMRI-Wellcome Trust Collaborative Research Program
Information provided by (Responsible Party):
LimmaTech Biologics AG

Brief Summary:
In this study, the tetravalent bioconjugate candidate vaccine Shigella4V will be tested to obtain first-in-human data on its safety and immunogenicity in infants and to identify the preferred dose of Shigella4V in 9 month old infants.

Condition or disease Intervention/treatment Phase
Shigellosis Biological: Shigella 4V Biological: MenACWY Biological: Rabies Biological: Diphtheria, Tetanus and Pertussis (DTaP) Biological: Placebo Phase 1 Phase 2

Detailed Description:

Shigella4V is a tetravalent bioconjugate vaccine including O antigen-polysaccharides of the most predominant Shigella serotypes.

The study will be conducted in two steps. In Step1: safety and reactogenicity of the vaccine will be evaluated first in adults and subsequently in children and infants through an age-descending and dose escalation approach. In Step 2: in order to further evaluate safety and to identify the optimum immunogenic dose, infants will be randomised to receive 1 of 4 different vaccine doses or control vaccine.

Adults will receive a 2 dose schedule, children and infants will receive a 3 dose schedule. For each vaccine dose, formulation with and without Aluminium adjuvant will be tested.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 592 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: This phase 1/2 trial is a multicentre, randomized, controlled, double blind, with two steps; a step 1 with a safety cohort and a step 2 with a dose-finding cohort. Safety of the vaccine will be evaluated first in adults and subsequently in children and infants through an age-descending and dose escalation approach (safety cohort, step 1). Following confirmation of vaccine safety, further cohorts of infants (dose-finding cohort) will be enrolled to evaluate immunogenicity of the vaccine at different doses and expand safety data (step 2). Vaccination in Step 1 will be staggered with adults being the first to be vaccinated and infants last. In step 2 infants will be vaccinated concurrently, with each group randomised to receive 1 of 4 different vaccine doses. A control vaccine will be used, and participants will be randomized at a ratio of 3:1 in adults, 2:1 in children, 2:1 in infants in step 1 and 8:1 in infants in step 2, to receive the candidate vaccine versus the control vaccine.
Masking: Double (Participant, Investigator)
Primary Purpose: Prevention
Official Title: Safety and Immunogenicity of a Shigella-Tetravalent Bioconjugate Vaccine: A Phase 1/2 Randomized Controlled and Age Descending Study Including Dose Finding in 9 Month Old Infants
Actual Study Start Date : September 2, 2019
Estimated Primary Completion Date : September 2021
Estimated Study Completion Date : January 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: NA (Non-adjuvanted) - very low dose - infants
Infants receive 3 very low doses of the non-adjuvanted investigational product
Biological: Shigella 4V
Non-adjuvanted and adjuvanted Shigella 4V administrated at 4 different doses: very low, low, medium and high.

Experimental: A (adjuvanted) - very low dose - infants
Infants receive 3 very low doses of the adjuvanted investigational product
Biological: Shigella 4V
Non-adjuvanted and adjuvanted Shigella 4V administrated at 4 different doses: very low, low, medium and high.

Experimental: NA (Non-adjuvanted) - low dose -infants
Infants receive 3 low doses of the non-adjuvanted investigational product
Biological: Shigella 4V
Non-adjuvanted and adjuvanted Shigella 4V administrated at 4 different doses: very low, low, medium and high.

Experimental: A (adjuvanted) - low dose - infants
Infants receive 3 low doses of the adjuvanted investigational product
Biological: Shigella 4V
Non-adjuvanted and adjuvanted Shigella 4V administrated at 4 different doses: very low, low, medium and high.

Experimental: NA (non-adjuvanted) - medium dose - infants
Infants receive 3 medium doses of the non-adjuvanted investigational product
Biological: Shigella 4V
Non-adjuvanted and adjuvanted Shigella 4V administrated at 4 different doses: very low, low, medium and high.

Experimental: A (adjuvanted) - medium dose - infants
Infants receive 3 medium doses of the adjuvanted investigational product
Biological: Shigella 4V
Non-adjuvanted and adjuvanted Shigella 4V administrated at 4 different doses: very low, low, medium and high.

Experimental: NA (non-adjuvanted) - medium dose - children
Children receive 3 medium doses of the non-adjuvanted investigational product
Biological: Shigella 4V
Non-adjuvanted and adjuvanted Shigella 4V administrated at 4 different doses: very low, low, medium and high.

Experimental: A (adjuvanted) - medium dose - children
Children receive 3 medium doses of the adjuvanted investigational product
Biological: Shigella 4V
Non-adjuvanted and adjuvanted Shigella 4V administrated at 4 different doses: very low, low, medium and high.

Experimental: NA (non-adjuvanted) - medium dose-adults
Adults receive 2 medium doses of the non-adjuvanted investigational product
Biological: Shigella 4V
Non-adjuvanted and adjuvanted Shigella 4V administrated at 4 different doses: very low, low, medium and high.

Experimental: A (adjuvanted) - medium dose - adults
Adults receive 2 medium doses of the adjuvanted investigational product
Biological: Shigella 4V
Non-adjuvanted and adjuvanted Shigella 4V administrated at 4 different doses: very low, low, medium and high.

Experimental: NA (non-adjuvanted) - high dose - infants
Infants receive 3 high doses of the non-adjuvanted investigational product
Biological: Shigella 4V
Non-adjuvanted and adjuvanted Shigella 4V administrated at 4 different doses: very low, low, medium and high.

Experimental: A (adjuvanted) - high dose - infants
Infants receive 3 high doses of the adjuvanted investigational product
Biological: Shigella 4V
Non-adjuvanted and adjuvanted Shigella 4V administrated at 4 different doses: very low, low, medium and high.

Experimental: NA (non-adjuvanted) - high dose - children
Chilldren receive 3 high doses of the non-adjuvanted investigational product
Biological: Shigella 4V
Non-adjuvanted and adjuvanted Shigella 4V administrated at 4 different doses: very low, low, medium and high.

Experimental: A (adjuvanted) - high dose - children
Chilldren receive 3 high doses of the adjuvanted investigational product
Biological: Shigella 4V
Non-adjuvanted and adjuvanted Shigella 4V administrated at 4 different doses: very low, low, medium and high.

Experimental: NA (non-adjuvanted) - high dose - adults
Adults receive 2 high doses of the non-adjuvanted investigational product
Biological: Shigella 4V
Non-adjuvanted and adjuvanted Shigella 4V administrated at 4 different doses: very low, low, medium and high.

Experimental: A (adjuvanted) - high dose - adults
Adults receive 2 high doses of the adjuvanted investigational product
Biological: Shigella 4V
Non-adjuvanted and adjuvanted Shigella 4V administrated at 4 different doses: very low, low, medium and high.

Experimental: MenACWY-Placebo
Adults receive one administration of MenACWY followed by one placebo administration
Biological: MenACWY
Control vaccine administrated to adults and infants

Biological: Placebo
Control administrated to adults

Rabies
Children receive three administrations of Rabies
Biological: Rabies
Control vaccine administrated to children

MenACWY-DTaP
Infants receive two administrations of MenACWY followed by DTaP administration
Biological: MenACWY
Control vaccine administrated to adults and infants

Biological: Diphtheria, Tetanus and Pertussis (DTaP)
Control vaccine administrated to infants




Primary Outcome Measures :
  1. Safety - Solicited Local and Systemic Adverse Events (AEs) [ Time Frame: during 7 days following each vaccination ]
    Safety and tolerability of the candidate vaccine Shigella4V as determined by occurrence, severity and relationship of solicited AEs

  2. Safety - Unsolicited Adverse Events (AEs) [ Time Frame: during 28 days following each vaccination ]
    Safety and tolerability of the candidate vaccine Shigella4V as determined by occurrence, severity and relationship of unsolicited AEs

  3. Safety - Serious Adverse Events (SAEs) [ Time Frame: throughout the study duration, up to 15 months ]
    Safety and tolerability of the candidate vaccine Shigella4V as determined by occurrence, severity and relationship of SAEs

  4. Immunology - change in serum immunoglobulin G (IgG) [ Time Frame: throughout the study, up to 15 months ]
    Serum IgG responses and fold-increases between post- and pre-vaccination samples from infants of step 2, as determined by enzyme-linked immunosorbent assay (ELISA) against lipopolysaccharide (LPS) corresponding to the 4 Shigella serotypes included in the Shigella4V bioconjugate.


Secondary Outcome Measures :
  1. Safety - clinically significant changes in cell blood count (CBC) with differentials [ Time Frame: throughout the study, up to 15 months ]
    Assess the safety of the candidate vaccine Shigella4V by measuring clinical significant changes in haematological safety parameters

  2. Safety - clinically significant changes in creatinine level [ Time Frame: throughout the study, up to 15 months ]
    Assess the safety of the candidate vaccine Shigella4V by measuring clinical significant changes in biochemical safety parameters

  3. Safety - clinically significant changes in alanine aminotransferase (ALT) level [ Time Frame: throughout the study, up to 15 months ]
    Assess the safety of the candidate vaccine Shigella4V by measuring clinical significant changes in biochemical safety parameters

  4. Safety - clinically significant changes in aspartate aminotransferase (AST) level [ Time Frame: throughout the study, up to 15 months ]
    Assess the safety of the candidate vaccine Shigella4V by measuring clinical significant changes in biochemical safety parameters

  5. Immunogenicity - change is serum IgG [ Time Frame: throughout the study, up to 15 months ]
    Serum IgG responses and fold-increases between post- and pre-vaccination samples from all participants of step 1, as determined by ELISA against LPS corresponding to the 4 Shigella serotypes included in the Shigella4V bioconjugate.

  6. Immunogenicity - change in anti-Shigella LPS antibody titre [ Time Frame: throughout the study, up to 15 months ]
    Percentage of participants (from step 1 and 2) achieving at least a four-fold rise in anti-Shigella LPS antibody titre after each injection compared to baseline.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   8 Months to 50 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

All ages

  • Healthy by medical history, laboratory findings and physical examination before entering into the study (Participants with a minor illness (such as mild diarrhoea, mild upper respiratory infection) without fever may be enrolled at the discretion of the investigator)
  • Seronegative for HIV, hepatitis B and C (as per screening laboratory tests)
  • Resident in the study area village during the whole trial period (Kilifi -Kilifi Health and Demographic Surveillance System (Described in more detail in the SSA); (Kericho-a 75km radius from the Kericho Clinical Research Centre).
  • Previously completed routine primary vaccinations (6,10 and 14 weeks or thereabouts) to the best knowledge of the participant/parent/guardian.
  • Signed/thumb written informed consent, in accordance with local practice, provided by adult volunteers (participants 18 years of age and older), parents or legal representatives for children and infants participants as applicable, who, in the opinion of the investigator, can and will comply with the requirements of the protocol
  • Demonstrated comprehension of the protocol procedures by passing score of 90% or better on a written/verbal comprehension test.

Adults

  • Female and male participants between, and including 18-50 years at the time of first vaccination
  • Female participants of non-childbearing potential may be enrolled in the study. Non-childbearing potential is defined as pre-menarche, current bilateral tubal ligation or occlusion, hysterectomy, bilateral ovariectomy or post-menopause. Female volunteers of childbearing potential may be enrolled in the study if the participant: has a negative urine pregnancy test at the day of screening and vaccinations, respectively, and

    • agree to use effective contraception for 30 days prior to vaccination and
    • agree to continue contraception at least for 2 months after completion of vaccination series.

Children and Infants

  • Female and male aged 9 months (+/- 1 month) old (infants) or between, and including, 2-5 years of age (children) at the time of the first vaccination
  • Born full-term (i.e. after a gestation period of 37 to less than 42 completed weeks)

Exclusion Criteria:

All ages

  • Any clinically significant deviation from the normal range in biochemistry or haematological blood tests.
  • Suspected or known hypersensitivity (including allergy) to any of the vaccine components or to previous vaccine, or to medicinal products or medical equipment whose use is foreseen in this study
  • Clinical conditions representing a contraindication to intramuscular vaccination and blood draws
  • Any confirmed or suspected immunosuppressive or immune-deficient condition.
  • Systemic administration of corticosteroids (PO/IV/IM): prednisone ≥20 mg/day, or equivalent for more than 14 consecutive days from birth (for infants) / within 90 days prior to informed consent. Inhaled except for doses > 800 mg/day and topical steroids are allowed.
  • Administration of antineoplastic or radiotherapy from birth / within 90 days prior to informed consent. Participants may be on chronic or as needed medications if, in the opinion of the site principal investigator or appropriate sub-investigator, they pose no additional risk to participant safety or assessment of reactogenicity and immunogenicity and do not indicate a worsening of medical diagnosis or condition
  • Known exposure to Shigella during lifetime of the subject
  • Concurrently participating in another clinical study, or participation in the preceding month, at any time during the study period, in which the participant has been or will be exposed to an investigational or a non-investigational vaccine/product (pharmaceutical product or device)
  • Acute disease and /or fever at the time of enrolment Note: enrolment may be postponed/delayed until such transient circumstances have terminated
  • History of any malignancy of lymphoproliferative disorder
  • Known to be part of study personnel or being a close family member to the personnel conducting this study.
  • Previous history of significant persistent neutropenia, or drug related Neutropenia
  • Adults with clinical wasting; children with weight-for-age Z score less than -3SD.
  • History of any chronic or progressive disease (e.g., neoplasm, insulin dependent diabetes, cardiac, renal or hepatic disease) that according to judgment of the investigator could interfere with the study outcomes or pose a threat to the participant's health
  • History of surgical splenectomy or Sickle cell disease (SCD test performed at KEMRI-CGMRC only).
  • Administration of immunoglobulin and/or any blood products within the three months preceding the first dose of study vaccine
  • Any medical, social condition, or occupational reason that, in the judgment of the investigator, is a contraindication to protocol participation or impairs the volunteer's/parent's/guardian's ability to give informed consent, increases the risk to the potential participant because of participation in the study, affect the ability of the volunteer to participate in the study or impair interpretation of the study data .

Adults

  • Women who are breastfeeding
  • History of chronic alcohol consumption and/or drug abuse. Chronic alcohol consumption is defined as: a prolonged period of frequent, heavy alcohol use; the inability to control drinking once it has begun; physical dependence manifested by withdrawal symptoms when the individual stops using alcohol; tolerance, or the need to use more and more alcohol to achieve the same effects; a variety of social and/or legal problems arising from alcohol use.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04056117


Contacts
Layout table for location contacts
Contact: Mainga Hamaluba, MD 730 162110 ext 254 Mainga Hamaluba <MHamaluba@kemri-wellcome.org>

Locations
Layout table for location information
Kenya
KEMRI-Centre Geographic Medical Research-COAST (KEMRI-CGMRC) Recruiting
Kilifi, Kenya, 230-80108
Contact: Mainga Hamaluba, MD         
Sponsors and Collaborators
LimmaTech Biologics AG
Kenya Medical Research Institute
KEMRI-Wellcome Trust Collaborative Research Program
Investigators
Layout table for investigator information
Principal Investigator: Mainga Hamaluba, MD KEMRI/Welcome Trust Research Programme,Kilifi, Kenya
Principal Investigator: Josphat Kosgei, MD Medical Research Institute, Kericho, Kenya

Publications:

Layout table for additonal information
Responsible Party: LimmaTech Biologics AG
ClinicalTrials.gov Identifier: NCT04056117     History of Changes
Other Study ID Numbers: S4V01
First Posted: August 14, 2019    Key Record Dates
Last Update Posted: September 9, 2019
Last Verified: September 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Dysentery, Bacillary
Enterobacteriaceae Infections
Gram-Negative Bacterial Infections
Bacterial Infections
Dysentery
Gastroenteritis
Gastrointestinal Diseases
Digestive System Diseases
Intestinal Diseases
Vaccines
Immunologic Factors
Physiological Effects of Drugs